Sarah B Gitto, PhD
Research Assistant Professor of Radiology
Department: Radiology
Contact information
Stellar Chance Laboratories
411 Curie Blvd, Rm 413A
Philadelphia, PA 19104
411 Curie Blvd, Rm 413A
Philadelphia, PA 19104
Publications
Education:
B.S. (Molecular Biology and Microbiology)
University of Central Florida, 2011.
B.S. (Health Sciences, Pre-Clinical Track )
University of Central Florida, 2011.
M.S. (Biomedical Sciences)
University of Central Florida, 2014.
Ph.D. (Biomedical Sciences)
University of Central Florida, 2017.
M.S. (Translational Science)
University of Pennsylvania, 2022.
Permanent linkB.S. (Molecular Biology and Microbiology)
University of Central Florida, 2011.
B.S. (Health Sciences, Pre-Clinical Track )
University of Central Florida, 2011.
M.S. (Biomedical Sciences)
University of Central Florida, 2014.
Ph.D. (Biomedical Sciences)
University of Central Florida, 2017.
M.S. (Translational Science)
University of Pennsylvania, 2022.
Selected Publications
Nakkina SP, Medvedev S, Ma K, Anderson M, Simpkins F, Powell DJ Jr., Gitto SB: VEGF inhibition enhances immune checkpoint blockade efficacy in ovarian cancer. In Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research September 2025.Riad A, McAuthur A, Babazada H, Mankoff D, Mach RH, Farwell FD, Gitto SB: Preclinical evaluation of PTT, an At-211-labeled rucaparib analogue, as a therapeutic agent for cancer therapy. Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research September 2025.
Gitto SB, Riad A, McArthur A, Simpkins F, Pryma DA, Farwell MD: PARP-targeted alpha therapy for the treatment of PARP-inhibitor resistant ovarian cancer. In Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research September 2025.
Babazada H, Martorano P, Lee H, Geng S, Batra V, Maris JM, Pryma DA, Gitto SB, Farwell MD.: PARP1-targeted alpha therapy enhances target expression. European Journal of Nuclear Medicine and Molecular Imaging 15(1): 63, June 2025.
Young A, Bagheri S, Kiani M, Gitto S, Sharaf O, Wu G, Lee J, Clark A, Zuckerman S, Lee H, Pantel A, Schubert E, Mankoff D, Mach R, McDonald E: Early reductions in [18F]FlourThanatrace uptake after PARP inhibitor therapy are prior to expected cell death. Journal of Nuclear Medicine June 2025.
Onecha VV, Suarez-Garcia D, Bosque JJ, Lee H, Simpkins F, Gitto SB, Pryma DA, Bertolet A.: Space- and time-defined Monte Carlo dosimetry explains ovarian cancer cell viability in targeted a-particle therapy with astatine 211-ParaThanatrace. International Journal of Radiation Oncology, Biology, and Physics June 2025.
Gitto SB, Pantel AR, Maxwell K, Pryma DA, Farwell MD, O'Brien SR, Clark AS, McDonald ES: [18F]FlourThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer. Communications Medicine 5(1): 90, March 2025 Notes: doi: 10.1038/s43856-025-00791-0.
Weeks JK, Pantel AR, Gitto SB, Liu F, Schubert EK, Pryma DA, Farwell MD, Mankoff DA, Mach RH, Simpkins F, Lin LL.: [18F]Fluorthanatrace PET in ovarian cancer: Comparison with [18F]FDG PET, lesion location, tumor grade, and breast cancer gene mutation status. Journal of Nuclear Medicine 66(1): 34-39, January 2025 Notes: doi: 10.2967/jnumed.124.267627.
Gitto SB, Medvedev S, Anderson M, Simpkins F, Powell DJ: Anti-angiogenics enhance immune checkpoint inhibitor efficacy in ovarian cancer. Journal for ImmunoTherapy of Cancer 12(supplement 2), November 2024 Notes: doi: 10.1136/jitc-2024-SITC2024.0769.
Gitto SB, Ihewulezi CN, Onecha V, Lee H, Suarez-Garcia D, Bosque J, Simpkins F, Bertolet A, Pryma DA: PARP-targeted theranostic radiopharmaceutical therapy for drug-resistant ovarian cancer. European Journal of Cancer 211(supplement 4)): 114580, October 2024 Notes: Doi: https://doi.org/10.1016/j.ejca.2024.114580.